This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in...
Seattle Genetics, Inc. announced dosing of the first patient in HER2CLIMB-02, a randomized phase III clinical trial evaluating investigational agent...
This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of capecitabine + lapatinib in participants with...
Results from TH3RESA, a Phase III clinical trial of Kadcyla (ado trastuzumab emtansine), also known as T-DM1, from Genentech/Roche, show...
Positive high-level results from the DESTINY-Breast02 Phase III trial of Enhertu (trastuzumab deruxtecan) versus physician’s choice of treatment showed the trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine (T-DM1)
AstraZeneca and Daiichi Sankyo Company, Limited announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan...
Seagen Inc. announced data from the Phase III HER2CLIMB-02 clinical trial of Tukysa (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla)
The Phase II/III GATSBY trial, designed to support a new indication for Kadcyla (ado-trastuzumab emtansine) from Roche + ImmunoGen in...
Background: Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable.
- Daiichi Sankyo Company, Limited announced that the first patient has been dosed in DESTINY-Breast04 , a global pivotal phase...